Olaparib maintenance therapy after platinum chemotherapy substantially prolonged PFS compared with placebo in newly diagnosed advanced ovarian cancer.
Patients in the real world setting were initiated at a lower dose and experienced fewer side effects than trial participants.
Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.
Olaparib Treatment May Improve Health-Related Quality of Life in Germline BRCA1/2-Mutated Ovarian CancerSeptember 07, 2018
Olaparib, may help to improve duration of good quality of life and quality-adjusted progression-free survival in germline BRCA1/2-mutated ovarian cancer.
For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.
Previous studies have suggested that analgesic medicine use may have a protective effect for patients with ovarian cancer.
It was suggested that estrogen alone may have a protective effect, decreasing the risk of breast cancer by 8% with every year of use.
The researchers enrolled 25 platinum-pretreated, immunotherapy-naïve patients with recurrent advanced epithelial ovarian cancer (EOC) for the trial.
Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.
Researchers randomly assigned 74 patients to receive everolimus plus letrozole daily or tamoxifen daily plus medroxyprogesterone daily on alternating weeks.
Previous epidemiological studies have indicated inconsistent results regarding the correlation between antidepressant use and ovarian cancer risk.
Hyperthermic intraperitoneal chemotherapy with surgery increases survival for epithelial ovarian cancer patientsJanuary 22, 2018
Ovarian cancer has high rates of mortality as it is often diagnosed in late stages with spread to the peritoneal surface.
Females with BRCA1 mutations in their germline have a high risk of HGSOC.
Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.
Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-mediated DNA damage.
Eligible patients had platinum-sensitive malignancies, had at least 2 previous platinum-based therapies, and had reached complete or partial response to the most recent platinum-based regimen.
First-line treatment failed to improve progression-free survival among women of European descent with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC).
Researchers examined the differences in outcomes in patients with ovarian cancer who received platinum-based chemotherapy and non-platinum based chemotherapy after relapse.
Patients in the olaparib arm experienced a 70% reduction in the risk of disease progression or death vs placebo.
Maintenance treatment with olaparib tablets may prolong PFS without negatively affecting quality of life among patients with relapsed ovarian cancer.
Researchers are developing vaccines for patients with ovarian or breast cancer, with timing and vector being increasingly important factors for establishing therapeutic efficacy.
Durvalumab plus olaparib or intermittent cediranib is clinically active and tolerable in treating female cancers.
This anti-CD27 antibody demonstrated clinical activity among and was well-tolerated by patients with solid tumors including melanoma, prostate cancer, and renal cell carcinoma.
Safety, tolerability, and efficacy of palbociclib in combination with cisplatin or carboplatin among patients with advanced/metastatic solid tumors.
Adding bevacizumab to platinum-based chemotherapy may improve survival among women with recurrent ovarian cancer.
Study findings show that "important disparities in use of end-of-life care persist among racial and ethnic minorities."
Approval was based on findings from the phase 3 NOVA trial, the results of which were published in The New England Journal of Medicine.
Access a detailed treatment regimen chart for ovarian cancer, with a focus on primary chemotherapy/primary adjuvant therapy with IV and IP options.
Combined liquid-based Pap and CT-DNA may be a new method for tumor-derived driver mutation screening in primary ovarian carcinoma.
Patients with newly diagnosed ovarian cancer rank nausea as the most concerning side effect associated with chemotherapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer
- Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy
- Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment
- Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer
- Rates of Adverse Events Similar Regardless of IMRT Boost Type